Press

Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing On the CSE

Oct 10 • 2 min read

Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received conditional approval to list Safe Supply’s common shares on the Canadian Securities Exchange (the “CSE”). Final approval and trading of the Company shares are subject to fulfilling customary CSE requirements….

Medicinal Mushroom Market Anticipated to Reach USD 62.0 Bn by 2032 with 8.7% CAGR | Analysis by Marketresearch.biz

Oct 9 • 11 min read

Rising demand for medicinal mushrooms, like reishi, cordyceps, lion’s mane, and chaga, is fueled by their delightful taste and health benefits. They’re becoming popular ingredients in various foods and drinks due to their unique flavors. Global Medicinal Mushroom Market witnessed a valuation of USD 27.5 Bn in 2022 and is anticipated to reach USD 62.0 Bn by 2032, exhibiting a CAGR of…

Atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 9 • 2 min read

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at…

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

Oct 9 • 4 min read

–Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” – – Highlights preclinical work done to support selection of a development candidate for the Company’s phenethylamine program – – Cybin to moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit titled “Making Psychedelic Clinical Trials…

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

Oct 5 • 3 min read

Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has received approval to have the common shares (“Common Shares“) of the Company listed on the Canadian…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435